Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive Bacteria
Open Access
- 1 June 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (11) , 1601-1607
Abstract
Background. Telavancin, a novel lipoglycopeptide, exerts concentration-dependent, rapid bactericidal activity on account of its multiple mechanisms ofKeywords
This publication has 14 references indexed in Scilit:
- Trends in Antimicrobial Drug Development: Implications for the FutureClinical Infectious Diseases, 2004
- Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteriaJournal of Antimicrobial Chemotherapy, 2004
- Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in PennsylvaniaAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activity of TD-6424 againstStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2003
- Community‐Acquired Methicillin‐ResistantStaphylococcus aureusInfections in France: Emergence of a Single Clone That Produces Panton‐Valentine LeukocidinClinical Infectious Diseases, 2002
- Epidemiology and Clonality of Community‐Acquired Methicillin‐ResistantStaphylococcus aureusin Minnesota, 1996–1998Clinical Infectious Diseases, 2001
- The Changing Epidemiology of Staphylococcus aureus?Emerging Infectious Diseases, 2001
- Four Pediatric Deaths From Community-Acquired Methicillin-Resistant Staphylococcus aureus--Minnesota and North Dakota, 1997-1999JAMA, 1999
- Staphylococcus aureusInfectionsNew England Journal of Medicine, 1998
- Community-Acquired Methicillin-Resistant Staphylococcus aureus in Children With No Identified Predisposing RiskJAMA, 1998